Preclinical News and Research

RSS

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Universitat Autònoma de Barcelona researchers have found a mycobacterium that is more effective in treating superficial bladder cancer and does not cause infections, unlike those used up to now.

6 Oct 2015

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) - a tumor necrosis factor alpha (TNF-α) inhibitor

5 Oct 2015

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

PTC Therapeutics, Inc., today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K.

5 Oct 2015

Plymouth University and Ingenza partner to develop efficient, scalable microbial production system for epidermicin

Ingenza is collaborating with researchers at Plymouth University to develop an efficient, scalable microbial production system for epidermicin, an exciting new antibiotic that rapidly kills methicillin-resistant Staphylococcus aureus and other harmful bacteria.

1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

AMO Pharma raises $25 million in private equity financing

AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.

30 Sep 2015

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and the circulating tumor cells that can cause a cancer to metastasize. The work was tested successfully in an animal model.

30 Sep 2015

Collaborative approach may speed discovery of new preventive treatments for Alzheimer's disease

The future success of Alzheimer's prevention research could depend on the ability of researchers from different clinical trials to build collaborative relationships that facilitate the sharing of information, resources and expertise that may speed the discovery of new preventive treatments, according to leading Alzheimer's researchers who published a Perspectives article, "CAP--advancing the evaluation of preclinical Alzheimer disease treatments," online today in Nature Reviews Neurology.

30 Sep 2015

Disruption of blood-CSF barrier may negatively affect progression of Alzheimer's disease

More and more data from preclinical and clinical studies strengthen the hypothesis that immune system-mediated actions contribute to and drive pathogenesis in Alzheimer's disease. The team of Roosmarijn Vandenbroucke in the Claude Libert Group (VIB/UGent) combined their knowledge and expertise related to inflammation with the expertise in Alzheimer's disease present in the Bart De Strooper Group (VIB/KU Leuven).

29 Sep 2015

New self-contained device could provide instant results to routine lab tests, accelerate treatment and diagnosis

Researchers at Houston Methodist, along with collaborators at two major Singapore institutions, have developed a lab in a needle device that could provide instant results to routine lab tests, accelerating treatment and diagnosis by days.

29 Sep 2015

Unique molecule can bind HIV-infected cells to killer T cells

A unique molecule developed at Duke Medicine, the University of North Carolina at Chapel Hill and MacroGenics, Inc., is able to bind HIV-infected cells to the immune system's killer T cells. It could become a key part of a shock-and-kill strategy being developed in the hope of one day clearing HIV infection.

29 Sep 2015

Mediso USA announces tenth site of integrated preclinical nanoScan systems

Mediso USA is proud to announce the tenth site of integrated preclinical multimodality imagers of the nanoScan Family in North America, at the preeminent Cold Spring Harbor Laboratory. The nanoScan systems are developed and manufactured by Mediso Ltd., Hungary.

28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Combination of two targeted therapies increases survival in advanced melanoma

Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

28 Sep 2015

HIV cure research may shift from single-therapy development model to combination therapy trials

The next five years of HIV research should shift gears from the classic single-therapy development model to moving directly from in vitro studies to combination therapy trials, authors argue in a new paper published online today.

25 Sep 2015

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology.

24 Sep 2015

Stanford researchers successfully defeat C. difficile bacteria

Stanford University School of Medicine scientists successfully defeated a dangerous intestinal pathogen, Clostridium difficile, with a drug targeting its toxins rather than its life.

24 Sep 2015

Researchers develop promising metal-based compound to fight kidney cancer

Researchers developed a promising metal-based compound that destroys kidney cancer cells, while leaving normal cells unharmed. The findings may provide a new way of treating kidney cancer, opening the potential for more potent and less toxic therapies that would give cancer patients a better quality of life.

24 Sep 2015

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Longing to find a cure for cancer, HIV and other yet incurable diseases, researchers have already tried out hundreds of drugs, each requiring preclinical and clinical testing with live subjects. How many chemical agents more to try? Moving at such rate, will we find the cure during our lifetime? One of the easiest ways to speed up the drug development process is to simply perform it outside of the living body (e.g., by watching the substances react with the smallest pieces of live tissue and thus quickly predicting the overall effect it will make to the body when inside).

23 Sep 2015

Preclinical News and Research

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

Plymouth University and Ingenza partner to develop efficient, scalable microbial production system for epidermicin

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

AMO Pharma raises $25 million in private equity financing

Leading cancer researchers address eight 'big questions'

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Collaborative approach may speed discovery of new preventive treatments for Alzheimer's disease

Disruption of blood-CSF barrier may negatively affect progression of Alzheimer's disease

New self-contained device could provide instant results to routine lab tests, accelerate treatment and diagnosis

Unique molecule can bind HIV-infected cells to killer T cells

Mediso USA announces tenth site of integrated preclinical nanoScan systems

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Combination of two targeted therapies increases survival in advanced melanoma

HIV cure research may shift from single-therapy development model to combination therapy trials

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Stanford researchers successfully defeat C. difficile bacteria

Researchers develop promising metal-based compound to fight kidney cancer

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics